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cost of $78.98). The trial evaluated the percent of patients
achieving target intraocular pressures (IOPs). The cost 
of treatment to achieve the target was calculated as 
medication cost divided by effectiveness based on patients
achieving a target IOP of £17mmHg. This target was
chosen based on the Advanced Glaucoma Intervention
Study (AIGS) which indicated patients whose pressures
were below 18mmHg did not progress over a 6-year
period. The cost-effectiveness calculation was based on
cost and efﬁcacy data during the two-month study period.
RESULTS: With bimatoprost, 59% of patients reached
and maintained a target IOP of £17mm vs. 30% with
latanoprost plus adjunctive medicines (p < 0.05).
Common adjunctive medicines used were beta blockers
(44%), alpha-agonists (27%), CAIs (15%), Cosopt (9%),
and others (5%). The 2-month cost-effectiveness ratio
was $279 vs. $784 per successfully treated patient for
bimatoprost vs. the latanoprost plus adjunctive treat-
ments, respectively. The monthly incremental cost-
effectiveness ratio with brimonidine dominated all 
treatments with latanoprost. CONCLUSIONS: Due to a
greater percentage of glaucoma patients achieving a target
treatment of £17mmHg (considered effectiveness) with
bimatoprost, bimatoprost monotherapy has a more
favorable cost-effectiveness proﬁle than a combination of
latanoprost plus adjunctive treatments.
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OBJECTIVES: Glaucoma is a condition affecting one or
both eyes with raised intraocular pressure (IOP). The IOP
should be reduced to prevent progression of visual ﬁeld
loss. The objective of the present study was to com-
pare the cost-effectiveness of brimonidine tartate 0.2%
(Alphagan) with dorzolamide 2% (Trusopt) as adjunctive
therapies to beta-blockers in the treatment of adult glau-
coma patients in Norway. METHODS: A model based
on effectiveness and resource-use data from an RCT was
constructed. The RCT covered 106 adult patients having
beta-blockers with inadequately controlled IOP. The
major cost-driver was patients who did not reach target
IOP (17mmHg) and needed additional adjunctive thera-
pies. The change to another adjunctive therapy in the
model triggered more expensive medication and extra
follow-up visits at the ophthalmologist. The model
analysed cost-effectiveness from a societal perspective
within a 3-months time horizon. Norwegian unit costs
were included. The measure of effectiveness was “patients
achieving target IOP”. To handle uncertainty sensitivity
analyses (one-way, break-even, extreme scenario) were
undertaken. RESULTS: The RCT showed that 78% of
the patients using brimonidine and 37% using dorzo-
lamide achieved target IOP. The baseline cost-
effectiveness of brimonidine was NOK 1234 per patient
achieving target IOP compared with NOK 2769 for dor-
zolamide (1€ = 7.28 NOK). These results were strength-
ened by the fact that brimonidine was cheaper and more
effective (dominating strategy) for all IOP levels between
13–20mmHg. Even in the worst case brimonidine was
still cost-effective comparing with the best case for dor-
zolamide. The break-even price for brimonidine was
NOK 634 compared with NOK 133 in the baseline analy-
sis. CONCLUSION: Brimonidine was more cost-effective
(dominating) as adjunctive-therapy to beta-blockers than
dorzolamide. Based on this result Norwegian ophthal-
mologists and others should consider brimonidine in
future decision-making regarding choice of adjunctive
therapies in glaucoma treatment.
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OBJECTIVES: To evaluate the cost-effectiveness of
bimatoprost 0.03% versus a combination product of
timolol 0.5% and dorzolamide 2.0% in the treatment 
of glaucoma. METHODS: A pharmacoeconomic model
was constructed based on a 3-month randomized con-
trolled efﬁcacy-trial comparing Lumigan (bimatoprost
0.03%, a prostamide AWP of $53.13) and Cosopt (a
ﬁxed combination product of timolol 0.5% and dorzo-
lamide 2.0% AWP of $43.85). The trial evaluated the
percent of patients achieving target intraocular pressures
(IOPs) throughout the day. The cost of treatment to
achieve target was calculated as medication cost/expected
effectiveness based on patients achieving a target IOP of
<17mmHg. Cost-effectiveness was based on three
months of the trial treatment. RESULTS: With bimato-
prost, 30% of patients reached and maintained a target
IOP of <17mmHg for all measurements throughout the
day vs. 17% with the combination product (p <0.05). At
three-months, cost-effectiveness ratios were $531 vs.
$774 per successful patient for bimatoprost vs. the com-
bination-product. The incremental cost-per additional
treatment success with bimatoprost was $214. CON-
CLUSIONS: Due to a greater percentage of glaucoma
patients achieving ideal target treatment goals (considered
effectiveness) with bimatoprost 0.03%, bimatoprost
monotherapy has a more favorable cost-effectiveness
proﬁle than a combination of timolol 0.5% and dorzo-
lamide 2.0%.
